JQ1 not only potently impairs tumor cell proliferation, cell transformation and in vivo tumor growth in YAP/TAZ-addicted breast, liver and pancreatic cancer models; but also sensitizes BRAF-mutant melanoma cells to vemurafenib treatment [171]. Here, BRAF is linked to melanoma.